DZ Bank analyst Elmar Kraus downgraded Gilead Sciences to Hold from Buy with a $90 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GILD:
- Arcellx Soars on Key Deal with Gilead’s Kite
- ImmunoGen Joins hands with Gilead on AML Therapy
- Daiichi data competitive to Trodelvy, but 2 years behind Gilead, says Piper
- Gilead’s Kite Pharma, Daiichi Sankyo announce partnership revision
- Kite, Daiichi Sankyo announces changes to Yescarta licensing deal in Japan